MITSUI CHEMICALS, INC.

Rege Nephro Secures $150 Million in Series B Funding to Advance Kidney Disease Therapies

8 months ago

• Rege Nephro has successfully raised $22.5 billion yen ($150 million) in Series B funding to advance clinical trials for kidney disease therapies. • The funding will support Phase II trials of RN-014, a retinoic acid receptor agonist, for Autosomal Dominant Polycystic Kidney Disease (ADPKD) and preparations for US trials. • Funds will also facilitate preclinical trials for RN-032, a cell therapy targeting Chronic Kidney Disease (CKD) using nephron progenitor cells. • The investment underscores confidence in Rege Nephro's iPSC-based technology and its potential to address unmet needs in kidney disease treatment.